A Leading European Oncology Research Centre, Europe, 2020

The oncology centre developed a novel liquid biopsy biomarker platform for early cancer detection but lacked internal capacity to navigate complex In Vitro Diagnostics (IVD) regulatory approval and structure a venture spinout. The client encountered complex market positioning and operational challenges in commercialising high-potential intellectual property assets while navigating tight regulatory standards and evolving international competition.

Oxford Oracle delivered an end-to-end commercialisation strategy, conducting regulatory pathway mapping, market pricing analysis, and venture deal structuring for early-stage investors. Oxford Oracle deployed a multidisciplinary advisory team to execute comprehensive technical due diligence, design bespoke commercialisation roadmaps, and establish standardized stage-gate evaluation metrics. This comprehensive initiative significantly accelerated time-to-market for novel inventions while safeguarding core institutional IP rights and fostering regional economic growth.

The spinout entity secured €6.2 million in seed and syndicate venture capital, completed CE-In Vitro Diagnostics (IVD) mark registration, and launched clinical validation trials across 6 European university hospitals. Furthermore, the engagement established a permanent, scalable operational blueprint, driving long-term strategic alignment, continuous revenue growth, and enhanced institutional reputation across global innovation networks.